Market Report Source

Overview

Introduction

This analysis examines the historical and forecast performance for Genentech in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Genentech’s performance against key rivals in the ethical pharmaceutical sector *Understand Genentech’s dominance of the monoclonal antibody sector *Learn how indication broadening of Rituxan and Avastin will be the key growth strategy for Genentech 2005-2011

Table of Contents

CHAPTER 1 EXECUTIVE SUMMARY

Key findings

Historical and forecast ethical sales performance

Therapeutic strategy

Molecule type, externalization and geographic strategies

Molecule type strategy

Externalization strategy

Geographic strategy

Launch and expiry outlook

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

CHAPTER 2 CORPORATE HISTORY

Key findings

Background

Key corporate developments

Founding

Genentech’s first product

Genentech’s first mAb therapy

Genentech timeline

M&A history

Genentech’s history with its partner Roche

Genentech’s agreement with Roche

Genentech’s closest biotech peer seems to be following a growth by acquistion strategy

Current corporate structure

Current management team

CHAPTER 3 HISTORICAL PERFORMANCE

Key findings

Revenue and growth rate analysis, 2002-05

Revenue and growth rate vs. peer set

Product analysis, 2002-05

Growth drivers and resistors

Operating revenue and cost analysis, 2002-05

Absolute P&L

Historical perfomance against corporate goals

Genentech’s historical corporate goals

CHAPTER 4 FORECAST PERFORMANCE

Key findings

Revenue and growth rate analysis, 2005-11

Product analysis, 2005-11

Therapy area analysis, 2005-11

Therapy area focus

Launch and expiries analysis, 2005-11

Launch portfolio

Core portfolio

Expiry portfolio

Launch/core/expiry configuration

Externalization analysis, 2005-11

Geographic analysis, 2005-11

Molecule type analysis, 2005-11

CHAPTER 5 KEY PRODUCTS AND COMPETITORS

Key findings

Overview

Oncology

Avastin

Overview

Sales forecast

Newsflow

Competitive landscape

Rituxan

Overview

Sales forecast – Oncology

Newsflow – Oncology

Competitive landscape – Oncology

Herceptin

Overview

Sales forecast

Newsflow

Competitive landscape

Tarceva

Overview

Sales forecast

Newsflow

Competitive landscape

Key oncology competitors

Insulated from Big Pharma and biotech competition

Rituximab – monopoly on targeted NHL market

Domination of targeted breast cancer market

Tykerb as potential long-term threat

Tykerb is illustrative of small molecule vs. biologic threat in cancer

Small molecule ‘multi-targeted’ drugs provide potential competition

Tarceva vs. Iressa – Genentech prevails over AstraZeneca

Overview of key competition in oncology market

AIID (Arthirits, Inflammation and Immune Disorders)

Rituxan RA – Rheumatoid arthritis

Overview

Sales forecast – Rheumatoid arthritis

Newsflow – Rheumatoid arthritis

Competitive landscape – Rheumatoid arthritis

AIID competitors

Significant competition for Genentech

Other

Lucentis (ranibizumab)

Overview

Sales forecast

Newsflow

Competitive landscape

Other competitors

Significant opportunity for Genentech

R&D pipeline

R&D pipeline

CHAPTER 6 APPENDIX

IMS vs. company-reported data reconciliation

Abbreviations

List of Tables

Table 1: Roche Group Corporate Executive Committee

Table 2: Peer set overview

Table 3: P&L ($m), 2002-05

Table 4: P&L (% of total revenues), 2002-05

Table 5: Product portfolio overview, sales ($m), 2005-11

Table 6: Therapy area overview, sales ($m), 2005-11

Table 7: Launch portfolio overview, sales ($m), 2005-11

Table 8: Core portfolio overview, sales ($m), 2005-11

Table 9: Expiry portfolio overview, sales ($m), 2005-11

Table 10: Externalization strategy overview

Table 11: Molecule type overview, sales ($m), 2005-11

Table 12: Key products overview

Table 13: Avastin: overview

Table 14: Avastin: sales forecast ($m), 2005-11

Table 15: Avastin: newsflow

Table 16: Avastin vs. Erbitux in the US

Table 17: Rituxan: overview

Table 18: Rituxan: sales forecast ($m), 2005-11

Table 19: Rituxan: newsflow

Table 20: Herceptin: overview

Table 21: Herceptin: sales forecast ($m), 2005-11

Table 22: Herceptin: newsflow

Table 23: Tarceva: overview

Table 24: Tarceva: sales forecast ($m), 2005-11

Table 25: Tarceva: newsflow

Table 26: Rituxan: overview

Table 27: Rituxan: sales forecast ($m), 2005-11

Table 28: Rituxan: newsflow

Table 29: Tarceva: overview

Table 30: Lucentis: sales forecast ($m), 2005-11

Table 31: Lucentis: newsflow

Table 32: Genentech’s R&D pipeline

Table 33: Genentech’s indication broadening pipeline (Phase I-Registration)

List of Figures

Figure 1: Historical and forecast ethical sales performance, Genentech and Biotech peer set (% CAGR)

Figure 2: Therapeutic focus vs. Biotech peer set (%)

Figure 3: Biologic, externalization and US market dependency vs. peer set, 2005-11 (%)

Figure 4: Launch, core and expiry vs. peer set, absolute sales growth, 2005-11 (sales as % of 2005 sales)

Figure 5: SWOT analysis of Genentech

Figure 6: Genentech timeline

Figure 7: Corporate structure

Figure 8: Revenue & growth rate (ethical sales) ($m), 2002-05

Figure 9: Ethical revenue ($m) and growth rate (%) vs. peer set, 2002-05

Figure 10: Growth drivers/resistor products of historical revenue performance ($m), 2002-05

Figure 11: P&L ($m), 2002-05

Figure 12: P&L (% of total revenues), 2002-05

Figure 13: Operating cost ratio vs. peer set, 2002-05

Figure 14: Ethical revenue ($m) and growth rate (%), 2005-11

Figure 15: Top five products by sales, 2005 & 2011

Figure 16: Growth drivers and resistors by product, 2005-11

Figure 17: Key strategic products, sales ($m), 2005-11

Figure 18: Ethical sales by therapy area ($m), 2005-11

Figure 19: Growth drivers and resistors by therapy area (%), 2005-11

Figure 20: Ethical sales by therapy area (%), 2005-11

Figure 21: Therapy area focus compared with peer set (% total ethical sales), 2005 & 2011

Figure 22: Launch schedule, sales ($m), 2005-11

Figure 23: Core products sales growth ($m), 2005-11

Figure 24: Expiry schedule, sales ($m), 2005-11

Figure 25: Launch, core and expiry, sales ($m), 2005-11

Figure 26: Launch, core and expiry vs. peer set, absolute sales growth (sales as % of 2005 sales), 2005-11

Figure 27: Externalization dependency, sales ($m), 2005-11

Figure 28: Growth drivers and resistors, externally vs. internally discovered products, sales ($m), 2005-11

Figure 29: Externalization dependency vs. peer set, % total sales, 2005 & 2011

Figure 30: Geographical sales breakdown ($m), 2005-11

Figure 31: Growth drivers and resistors by geography, sales ($m), 2005-11

Figure 32: US dependency vs. peer set, % total sales, 2005 & 2011

Figure 33: Molecule type sales breakdown ($m), 2005-11

Figure 34: Growth drivers and resistors by molecule type, sales ($m), 2005-11

Figure 35: Biologics dependency vs. peer set, % total sales, 2005 & 2011

Figure 36: Direct competition for Rituxan in NHL

Figure 37: Direct competition in the targeted breast cancer market

Figure 38: Direct competition in the colorectal cancer market

Figure 39: Direct competition in targeted NSCLC market

Figure 40: Direct competition in the AIID biologics market

Figure 41: Direct competition in the wet-AMD market

Figure 42: IMS vs. company-reported ethical sales discrepancy ($m), 2005

Figure 43: IMS vs. company-reported ethical sales forecast growth rates (%), 2005-11